Viveve Medical, Inc. (VIVE) Analysts See $-0.38 EPS

July 14, 2018 - By Richard Doty

Analysts expect Viveve Medical, Inc. (NASDAQ:VIVE) to report $-0.38 EPS on August, 9.They anticipate $0.16 EPS change or 29.63 % from last quarter’s $-0.54 EPS. After having $-0.49 EPS previously, Viveve Medical, Inc.’s analysts see -22.45 % EPS growth. The stock decreased 2.70% or $0.07 during the last trading session, reaching $2.52. About 177,236 shares traded. Viveve Medical, Inc. (NASDAQ:VIVE) has declined 65.48% since July 14, 2017 and is downtrending. It has underperformed by 78.05% the S&P500.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity. The company has market cap of $78.80 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories. It currently has negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

More notable recent Viveve Medical, Inc. (NASDAQ:VIVE) news were published by: which released: “Viveve Reports Preliminary Second Quarter 2018 Revenue of $5.5 million” on July 10, 2018, also with their article: “Viveve Submits VIVEVE II Clinical Study 30-Day Patient Safety Data to FDA” published on July 03, 2018, published: “40 Biggest Movers From Friday” on June 18, 2018. More interesting news about Viveve Medical, Inc. (NASDAQ:VIVE) were released by: and their article: “38 Stocks Moving In Tuesday’s Mid-Day Session” published on June 19, 2018 as well as‘s news article titled: “After-Hours Stock Movers 06/18: (GEVO) (VIVE) (CL) Higher; (PAGS) (TELL) (DEA) Lower (more…)” with publication date: June 18, 2018.

Viveve Medical, Inc. (NASDAQ:VIVE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.